Tatovic, Danijela  ORCID: https://orcid.org/0000-0002-3879-2686 and Dayan, Colin M ORCID: https://orcid.org/0000-0002-6557-3462
2021.
Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes.
Diabetic Medicine
38
, e14696.
10.1111/dme.14696
|
Abstract
For almost a hundred years, the management of Type 1 diabetes has not advanced beyond insulin replacement. However, insulin does not provide satisfactory glycaemic control in the majority of individuals and there remains a major unmet need for novel treatments for Type 1 diabetes. Immunomodulation to preserve beta-cell function offers the prospect of making treatment with insulin easier and/or preventing the need for insulin, particularly when it comes to novel low-risk immunotherapies. Led by the concept that the best insulin-producing cell is a patient's own beta-cell, the Type 1 diabetes scientific community has a challenging task ahead—to fundamentally change the management of this devastating disease by using low-risk immunotherapy to preserve endogenous beta-cell function and make metabolic control substantially easier. In that way, insulin and/or beta-cell replacement (stem cell or transplantation) should in the future be considered rescue therapies reserved for delayed presentations.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Medicine |
| Publisher: | Wiley |
| ISSN: | 0742-3071 |
| Date of First Compliant Deposit: | 7 October 2021 |
| Date of Acceptance: | 22 September 2021 |
| Last Modified: | 10 Nov 2022 09:51 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/144728 |
Citation Data
Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric